期刊
ANNALS OF NEUROLOGY
卷 90, 期 2, 页码 315-318出版社
WILEY
DOI: 10.1002/ana.26144
关键词
-
资金
- MRC [CARP MR/T024402/1]
- MRC [MR/T024402/1] Funding Source: UKRI
Vigilance is needed for rare cases of Guillain-Barre syndrome following vaccination, and robust surveillance programs are recommended to assess causality.
Although SARS-CoV-2 vaccines are very safe, we report 4 cases of the bifacial weakness with paresthesias variant of Guillain-Barre syndrome (GBS) occurring within 3 weeks of vaccination with the Oxford-AstraZeneca SARS-CoV-2 vaccine. This rare neurological syndrome has previously been reported in association with SARS-CoV-2 infection itself. Our cases were given either intravenous immunoglobulin, oral steroids, or no treatment. We suggest vigilance for cases of bifacial weakness with paresthesias variant GBS following vaccination for SARS-CoV-2 and that postvaccination surveillance programs ensure robust data capture of this outcome, to assess for causality. ANN NEUROL 2021
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据